Arrivent Biopharma Inc. AVBP
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Arrivent Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of differentiated medicines to address unmet medical needs in patients with difficult-to-treat diseases, starting with cancers. Its lead development candidate, firmonertinib, a tyrosin…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees77
TickerAVBP
Statistics
Market Cap$1.41B
Revenue (TTM)—
Net Income-$166.3M
Net Margin—
EPS$-4.32
P/E-7.13
P/S—
P/B4.21
EV/EBITDA-6.16
ROE-55.2%
Dividend Yield—
Price$31.05
Data: Twelve Data · Revenue = mcap / P/S